The epidermal growth factor receptor (EGFR) is an important target forthe treatment of head and neck squamous cell carcinoma (HNSCC). Clinical strategies to target EGFR have focused on monoclonal antibodies (mAbs), such as cetuximab. Cetuximab executes its antitumor effect in vivo via blockade of receptor-ligand interactions and engagement of Fcgamma receptors on immune effector cells which trigger antibody-dependent cell-mediated cytotoxicity (ADCC). Our preliminary studies demonstrate that tumor cell-autonomous expression of TGF-beta is a key molecular determinant of the de novo or acquired resistance of cancers to EGFR-targeted mAb, and provide a rationale for enhancing the antitumor efficacy of anti-EGFR mAb by combinatorial- or bi-functional antibody-based strategies to simultaneously counteract TGF-beta in the tumor microenvironment.
The aims of the project are designed to advance the clinical translation of this strategy for treatment of HNSCC;
Specific Aim I : Determine whether tumor cell-autonomous expression of TGF-beta inhibits cetuximab-induced ADCC in patients with HNSCC.
Specific Aim II : Determine the in vivo antitumor efficacy and toxicity of dual blockade of EGFR and TGF-beta using HNSCC patient-derived tumor xenografts in mice.
Specific Aim III : Determine the clinical relevance of TGF-beta as a molecular determinant of resistance to cetuximab in patients with HNSCC, and evaluate the clinical safety of a novel bi-functional anti-EGFR antibody that can sequester and block TGF-beta in the tumor microenvironment. This project addresses the urgent need for effective tumor-targeted therapeutic strategies against HNSCC by: (1) Establishing the role of tumor cell-autonomous expression of TGF-beta as a key mechanism and clinical biomarker of resistance to cetuximab in patients with HNSCC;(2) Improving the treatment of patients with HNSCC and other cancers via novelcombinatorialor bi-functional antibody-based strategies that simultaneously target and counteract EGFR and TGF-beta in the tumor microenvironment. The project will leverage the expertise and resources of the JHU Tissue Core, Biostatistics Core, and will interact with Projects 1 and 4 of the SPORE-Head and Neck Cancer.

Public Health Relevance

This research and clinical project is designed to establish the role of tumor cell-autonomous expression of TGF-beta as a clinical determinant and biomarker of resistance of head and neck cancers(HNSCC) to cetuximab, and improve the treatment of HNSCC via novel combinatorial- or bi-functional antibody-based strategies that simultaneously target and counteract EGFR and TGF-beta in the tumor microenvironment.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Specialized Center (P50)
Project #
5P50DE019032-13
Application #
8703523
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
13
Fiscal Year
2014
Total Cost
$362,354
Indirect Cost
$131,919
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Li, Ryan; Faden, Daniel L; Fakhry, Carole et al. (2015) Clinical, genomic, and metagenomic characterization of oral tongue squamous cell carcinoma in patients who do not smoke. Head Neck 37:1642-9
Gaykalova, Daria A; Mambo, Elizabeth; Choudhary, Ashish et al. (2014) Novel insight into mutational landscape of head and neck squamous cell carcinoma. PLoS One 9:e93102
Dýýsouza, Gypsyamber; Carey, Thomas E; William Jr, William N et al. (2014) Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr 65:603-10
Wu, Chao-Yi; Yang, Li-Hua; Yang, Huang-Yu et al. (2014) Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res 20:644-57
Bishop, Justin A; Yonescu, Raluca; Batista, Denise et al. (2014) Mucoepidermoid carcinoma does not harbor transcriptionally active high risk human papillomavirus even in the absence of the MAML2 translocation. Head Neck Pathol 8:298-302
Sun, Wenyue; Gaykalova, Daria A; Ochs, Michael F et al. (2014) Activation of the NOTCH pathway in head and neck cancer. Cancer Res 74:1091-104
Fakhry, Carole; Gillison, Maura L; D'Souza, Gypsyamber (2014) Tobacco use and oral HPV-16 infection. JAMA 312:1465-7
Izumchenko, Evgeny; Chang, Xiaofei; Michailidi, Christina et al. (2014) The TGF?-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors. Cancer Res 74:3995-4005
Bishop, Justin A; Yonescu, Raluca; Batista, Denise et al. (2014) Glandular odontogenic cysts (GOCs) lack MAML2 rearrangements: a finding to discredit the putative nature of GOC as a precursor to central mucoepidermoid carcinoma. Head Neck Pathol 8:287-90
Bishop, Justin A; Antonescu, Cristina R; Westra, William H (2014) SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract. Am J Surg Pathol 38:1282-9

Showing the most recent 10 out of 45 publications